Background
Methods
Data collection
Definitions
Statistical analysis
Results
General characteristics
No. of patients (%) |
P value*
| ||||
---|---|---|---|---|---|
Non-BSI (n = 196) | BSI (n = 26) | ||||
Gender | |||||
Male | 141 | (72) | 17 | (65) | 0.492 |
Female | 55 | (28) | 9 | (35) | |
Age ≥ 65 y/o | 127 | (65) | 19 | (73) | 0.402 |
Myeloma subgroup | |||||
IgG | 95 | (48) | 13 | (50) | 0.741 |
IgA | 63 | (32) | 9 | (35) | |
Light chain disease | 29 | (15) | 4 | (15) | |
Other typesa
| 9 | (5) | 0 | (0) | |
Immunoglobulin status | |||||
Severe Ig deficiencyb
| 177 | (90) | 23 | (88) | 0.767 |
Others | 19 | (10) | 3 | (12) | |
ALC count ≥ 1000 (/ul) | 138 | (70) | 17 | (65) | 0.612 |
ISS Stage | |||||
I | 37 | (19) | 1 | (4) | |
II | 64 | (33) | 5 | (19) | |
III | 95 | (48) | 20 | (77) | 0.019 |
ECOG PS >2 | 59 | (30) | 17 | (65) | <.001 |
Hb < 10 (g/dL) | 108 | (55) | 21 | (81) | 0.015 |
Ca > 12.0 (mg/dL) | 14 | (7) | 5 | (19) (58) | 0.038 |
Cr ≥ 2.0 (mg/dL) | 55 | (28) | 15 | 0.002 | |
Induction chemotherapy | |||||
VAD-based | 57 | (29) | 13 | (50) | |
MP-based | 83 | (42) | 7 | (27) | 0.064 |
Othersc
| 30 | (15) | 1 | (4) | |
No | 26 | (13) | 5 | (19) |
Outcome analysis
Risk factors of BSI
Univariate | Multivariate | |||||
---|---|---|---|---|---|---|
Odds ratio | 95% CI |
P value* | Odds ratio | 95% CI |
P value* | |
Gender (female vs. male) | 1.36 | 0.571–3.266 | 0.49 | - | - | - |
Age (≥ 65 vs. < 65) | 1.48 | 0.591–3.681 | 0.40 | - | - | - |
Myeloma subgroup | ||||||
IgG vs. Non-IgG | 1.06 | 0.469–2.410 | 0.88 | - | - | - |
IgA vs. Non-IgA | 1.12 | 0.472–2.646 | 0.80 | |||
Immunoglobulin status | 1.18 | 0.324–4.303 | 0.80 | - | - | - |
Severe Ig deficiencya vs. Others | ||||||
ISS stage | ||||||
III vs. I/II | 3.54 | 1.365–9.203 | <0.01* | 2.69 | 1.003–7.190 | 0.049 |
ECOG PS | ||||||
Score > 2 vs. 0–2 | 4.39 | 1.849–10.403 | <0.01* | 3.58 | 1.478–8.690 | 0.005 |
Hb (< 10 g/dL vs. ≥ 10 g/dL) | 3.422 | 1.240–9.444 | 0.02* | - | - | - |
Ca (> 12 mg/dL vs. < 12 mg/dL) | 3.095 | 1.013–9.454 | 0.04* | - | - | - |
Cr (≥ 2.0 mg/dL vs. < 2.0 mg/dL) | 3.091 | 1.341–7.126 | 0.01* | - | - | - |
ALC (< 1000/cumm vs. ≥ 1000/cumm) | 1.251 | 0.527–2.968 | 0.61 |
Characteristics of BSI patients
BSI pathogens and antibiotics susceptibility
Serial number | BSI after ICT | ICT regimen | Catheter type | Definite CRIb
| Pathogen | Empirical antibiotics | Early death (< 100day) |
---|---|---|---|---|---|---|---|
Nosocomial BSIa
| |||||||
1 (90) | - | - | - | - |
Coagulase-negative Staphylococcus species
| Ceftazidime/isepamicin | Y |
2 (215) | Y | Thalidomide/dexamethasone | - | - |
Coagulase-negative Staphylococcus species
| Ceftazidime | - |
3 (79) | Y | VAD | Implanted port | Y |
Coagulase-negative Staphylococcus species
Klebsiella pneumoniae
| Teicoplanin/isepamicin | Y |
4 (27) | - | MP | - | - |
Klebsiella pneumoniae
| Cefepime | - |
5 (62) | Y | MPT | Non-tunneled CVC | Y |
Klebsiella pneumoniae
| Ciprofloxacin - > Imipenem/teicoplanin | Y |
6 (78) | - | - | - | - |
Escherichia coli
| Y | |
7 (198) | Y | VAD | Non-tunneled CVC | - |
Escherichia coli
| Cefuroxime/clindamycin | Y |
8 (168) | Y | VAD/thalidomide | Non-tunneled PICC | - |
Escherichia coli
| Imipenem/vancomycin/amikin | Y |
9 (175) | Y | VAD | - | - |
Escherichia coli
| Cefuroxime/metronidazole | - |
10 (150) | Y | VAD | - | - |
Enterobacter gergoviae
| Oxacillin | - |
11 (14) | Y | VAD | Implanted port | - |
Enterobacter cloacae
| - | |
12 (94) | - | VAD | Non-tunneled CVC | - |
Pseudomonas Aeruginosa
| Cefepime | Y |
13 (115) | Y | VAD | Implanted port | - |
Proteus mirabilis
| Levofloxacin | - |
14 (69) | Y | VAD | - | - |
Salmonella Enteritidis group D
| Ceftazidime | Y |
15 (114) | Y | VAD | Non-tunneled CVC | - |
Staphylococcus aureus
| - | |
16 (71) | - | - | Non-tunneled CVC | Y |
Serratia marcescens
| Y | |
17 (61) | Y | MP | Non-tunneled CVC | - |
Yeast like-Trichosporon asahii
| Cefepime/azithromycin | Y |
18 (18) | Y | VAD | - | - |
Yeast like-Candida albicans
| Ceftazidime/teicoplanin | Y |
Non-nosocomial BSI | |||||||
1 (221) | - | - | - | - |
Coagulase-negative Staphylococcus species
| Flomoxef | - |
2 (41) | Y | VAD | - | - |
Coagulase-negative Staphylococcus species
| Piperacillin/tazobactam | - |
3 (211) | Y | MP | - | - |
Coagulase-negative Staphylococcus species
| - | |
4 (205) | - | - | - | - |
Streptococcus
| Meropenem/vancomycin/metronidazole | Y |
5 (137) | - | - | - | - |
Streptococcus pneumoniae
| - | |
6 (6) | - | MP | - | - |
Escherichia coli
| Cephalexin/isepamicin | - |
7 (106) | - | VAD | Non-tunneled CVC | - |
Pseudomonas aeruginosa
| Cefoperazone | - |
8 (46) | Y | MP | Tunneled CVC (Permcath) | - |
Lactobacillus species
| Moxifloxacin | Y |